SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sanjivani Paranteral Ltd (531569)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531569 NSE: Pharmaceuticals & Drugs | Small Cap | Sanjivani Paranteral Share Price

₹150.25 1.45 (0.97%)

As on 05-Jun'26 09:07

Sanjivani Paranteral Ltd (531569)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531569 NSE: Pharmaceuticals & Drugs | Small Cap | Sanjivani Paranteral Share Price

₹150.25 1.45 (0.97%)

As on 05-Jun'26 09:07

Key Metrics
Valuation Multiples
Market Cap
₹183 Cr.
Current Price
₹150.3
52-Week Low / High
₹126 / 269
TTM EPS
₹5.6
TTM Sales
₹64.8 Cr.
Book Value per Share
₹39.4
P/E Ratio
26.40
Higher than its 5-year historical median
Industry PE
46.5
Price to Book (P/B)
3.78
In line with its 5-year historical median
Price to Sales (P/S)
2.82
In line with its 5-year historical median
EV/EBITDA
17.93
Lower than its 5-year historical median
Dividend Yield
0.21%
Profitability Efficiency
Return on Equity (ROE)
25.92%
Outperforms industry median
Return on Capital Employed (ROCE)
30.22%
Outperforms industry median
Return on Assets (ROA)
14.95%
Operating Profit Margin
14.7%
Net Profit Margin
11.56%
Gross Profit Margin
15.4%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
28.84%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
28.3%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
31.28%
Asset Quality
Promoter Holding
31.26%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹36 Cr.
Equity
₹12.3 Cr.
Face Value
₹10
All Time Low / High
₹1.76 / 396.95

Sanjivani Paranteral stock performance

Key Ratios
mw4me loader

Check Before You Invest

Quality

Somewhat Good

Valuation

Overvalued

Price Trend

Weak
Q.1 Is Sanjivani Paranteral Ltd a good quality company?
Sanjivani Paranteral Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Sanjivani Paranteral Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Sanjivani Paranteral Ltd vs industry peers?
Sanjivani Paranteral Ltd revenue CAGR is 33.78%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Sanjivani Paranteral Ltd?
Promoters hold 31.26% of the Sanjivani Paranteral Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Sanjivani Paranteral Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 17% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Sanjivani Paranteral Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % -7.3%-33%-227.3%0%-266%266.4%0%0%55.3%30.2%-
Value Creation
Index
-1.5NANANANA18.0NANA3.01.2-

Growth Parameters

Sales 11532.71825.116.425.130.635.554.470.165
Sales YoY Gr.--71.7%-45%39.7%-34.8%53.4%22%15.9%53.3%28.8%-
Adj EPS -25.2-46-90-3.7-3.21.54.74.256.45.6
YoY Gr.-NANANANANA214.8%-10.9%20.3%26.4%-
BVPS (₹) 29.7-14.8-89.6-80-82.9-52.8-7.6-3.122.130.839.4
Adj Net
Profit
-14.9-27.2-53.1-2.2-1.91.34.74.25.97.67
Cash Flow from Ops. 0.59.63.12.5-0.20.68.54.7-10.7-0.2-
Debt/CF from Ops. 139.76.315.819.4-280.1790.70.5-0.1-23.6-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales -5.4%33.8%31.8%28.8%
Adj EPS NANA10.7%26.4%
BVPS0.4%NANA39.3%
Share Price 18.3% 68.1% 30% -39.1%

Key Financial Parameters

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
-60-618.2172.54.43.9-2.7-17.9-78.447.32316.1
Op. Profit
Mgn %
-4.8-70.4-289.8-7-3.48.513.914.814.714.714.5
Net Profit
Mgn %
-12.9-83.1-295.5-8.7-11.35.115.311.810.810.810.7
Debt to
Equity
3.6-6.9-0.9-1-1-1-0.8-0.800.20.1
Working Cap
Days
284722649171179133128121124163150
Cash Conv.
Cycle
221567420-105-169-112-90-8203194

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales115331825162531355470
Operating Expenses + 121567027172326304660
Manufacturing Costs2221123345
Material Costs11328251591512192840
Employee Cost 3332223345
Other Costs 42340844851010
Operating Profit -6-23-52-2-1245810
Operating Profit Margin (%) -4.8%-71.2%-290.0%-7.0%-3.4%8.5%13.9%14.8%14.7%14.7%
Other Income + 1301002111
Exceptional Items 0000000000
Interest 9500100001
Depreciation 1111111111
Profit Before Tax -15-26-53-2-2155810
Tax -0-0-0-0-0-00012
Profit After Tax -15-26-53-2-215568
PAT Margin (%) -12.7%-80.3%-295.0%-8.2%-10.4%5.7%15.8%12.7%11.3%11.6%
Adjusted EPS (₹)-24.8-44.5-90.0-3.5-2.91.74.94.55.36.8
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%7.30%

Valuation of Sanjivani Paranteral - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 18-9-53-47-49-45-8-32637
Share Capital 66666810101212
Reserves 12-15-59-53-55-53-18-131425
Debt +6157454545423115
Long Term Debt12748853115
Short Term Debt4950413737370000
Minority Interest0000000000
Trade Payables63121211111114615
Others Liabilities 982189121210118
Total Liabilities 93602518161918214365

Fixed Assets

Net Fixed Assets +131110988781021
Gross Block22222222222223242738
Accumulated Depreciation9111213141415161718
CWIP 0000000000
Investments 0000000003
Inventories20102121251010
Trade Receivables4832551752517
Cash Equivalents 00000000102
Others Assets 127735446913
Total Assets 93602518161918214365

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + 01032-0195-11-0
PBT -15-17-53-2-2155810
Adjustment 962121-1111
Changes in Working Capital 6215530-24-1-18-10
Tax Paid -000-0-0-0-0-0-1-1
Cash Flow From Investing Activity + -10-00-0-0-1-1-12-6
Capex -10-00-0-0-1-1-3-11
Net Investments 00000000-98
Others 000000000-3
Cash Flow From Financing Activity + -1-10-3-20-0-8-4236
Net Proceeds from Shares 00000320252
Net Proceeds from Borrowing 8-5-34100000
Interest Paid -8-5-0-0-1-0-0-0-0-1
Dividend Paid 0000000000
Others 000-60-3-9-3-25
Net Cash Flow -1-0000-00-000

Financial Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)-58.98N/AN/AN/AN/AN/AN/AN/A54.0825.92
ROCE (%)-7.28N/AN/AN/AN/AN/AN/AN/A55.3230.22
Asset Turnover Ratio1.120.430.421.170.971.471.661.811.691.31
PAT to CFO Conversion(x)N/AN/AN/AN/AN/A11.81-1.83-0
Working Capital Days
Receivable Days181.80445.90378.4076.507054.8067.7035.4022.4054.80
Inventory Days67.60167.60124.1021.4024.8018.3015.6036.4050.5051.70
Payable Days29.8060.30108.10288.80460.60263.60326.70247.40124.7094.70

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Sanjivani Paranteral Ltd FAQs

The current trading price of Sanjivani Paranteral on 05-Jun-2026 09:07 is ₹150.2.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Jun-2026 the market cap of Sanjivani Paranteral stood at ₹182.8 Cr

The latest P/E ratio of Sanjivani Paranteral as of 04-Jun-2026 is 26.40.

The latest P/B ratio of Sanjivani Paranteral as of 04-Jun-2026 is 3.78.

The 52-week high of Sanjivani Paranteral is ₹268.8 and the 52-week low is ₹126.0.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sanjivani Paranteral is ₹64.76 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Sanjivani Paranteral Ltd is a average quality company.

The key valuation ratios of Sanjivani Paranteral Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Sanjivani Paranteral Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Sanjivani Paranteral Ltd

Sanjivani Parenteral was established in 1997 by A H Khemka, Ashwin Khemka and Somesh Khemka, under the technical direction of Mahendra Kalwankar. It is a research-based, international pharmaceutical company that provides a wide range of high quality products and services at affordable prices. The core product range of the company’s products includes oral solids, small volume parenterals and sterile powder formulations.

The company has grown many folds and aspires to be a respected research-based company. With its diverse product portfolio, it is rapidly expanding its reach to the global marketplace, riding on its success in India and in the world’s emerging and developed markets.

After establishing itself in India, Sanjivani has extended its reach globally by entering the markets of Asia, Europe, Africa and Latin America.  The company has active presence in countries like Russia, Ukraine, Uzbekistan, Turkmenistan, Fiji, Vietnam, Sri Lanka, Nepal, Malaysia, Thailand, Nigeria and Peru, to name a few.  Sanjivani Parenteral has also got its plant approved by the registration authorities of Congo, Sudan and Sri Lanka. It is making its presence felt in the world market now, through leveraging its manufacturing capacity, quality of products and international alliances.

International business contributes about 30% of the company’s revenue and is set to grow to more than 50% in the coming two years. This includes the sales of Sanjivani’s own brands and the revenue from the contract manufacturing services that the company provides to its overseas clients. The company is in the making of a strong base to broaden its horizons. 

Sanjivani has been a regular supplier to the armed forces’ hospitals in India. Furthermore, many government and private hospitals have availed of the products and services offered by Sanjivani across the country.  The company also has its own marketing operations in India and boasts of over 1000 distributors all over India.

Products

  • Therapeutic Products
  • Animal Products
  • Key Products
  • Oral Solids
You have 0 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×